Integra LifeSciences (NASDAQ:IART) Reaches New 52-Week Low at $24.16

Integra LifeSciences Holdings Co. (NASDAQ:IART - Get Free Report)'s share price reached a new 52-week low on Monday . The company traded as low as $24.16 and last traded at $25.06, with a volume of 600287 shares changing hands. The stock had previously closed at $28.89.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. StockNews.com downgraded shares of Integra LifeSciences from a "buy" rating to a "hold" rating in a research report on Tuesday, April 30th. JMP Securities reduced their price objective on shares of Integra LifeSciences from $55.00 to $49.00 and set a "market outperform" rating for the company in a research note on Thursday, February 29th. Truist Financial reduced their price objective on shares of Integra LifeSciences from $46.00 to $41.00 and set a "hold" rating for the company in a research note on Friday, March 1st. Finally, Citigroup raised shares of Integra LifeSciences from a "sell" rating to a "neutral" rating and set a $38.00 price objective for the company in a research note on Wednesday, April 3rd. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $44.89.

Integra LifeSciences Trading Down 19.9 %

The company has a debt-to-equity ratio of 0.94, a quick ratio of 2.18 and a current ratio of 3.45. The firm has a market cap of $1.82 billion, a PE ratio of 27.88, a PEG ratio of 0.87 and a beta of 1.17. The stock's 50 day simple moving average is $33.75 and its 200 day simple moving average is $38.44.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last announced its quarterly earnings data on Wednesday, February 28th. The life sciences company reported $0.89 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.90 by ($0.01). Integra LifeSciences had a net margin of 4.39% and a return on equity of 15.19%. The business had revenue of $397.00 million during the quarter, compared to analysts' expectations of $399.30 million. During the same period last year, the company posted $0.94 EPS. Integra LifeSciences's revenue for the quarter was down .3% on a year-over-year basis. On average, sell-side analysts forecast that Integra LifeSciences Holdings Co. will post 3.19 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Integra LifeSciences

A number of institutional investors have recently made changes to their positions in IART. Signaturefd LLC raised its holdings in Integra LifeSciences by 248.5% during the 4th quarter. Signaturefd LLC now owns 582 shares of the life sciences company's stock valued at $25,000 after buying an additional 415 shares during the last quarter. Hexagon Capital Partners LLC raised its holdings in Integra LifeSciences by 123.3% during the 4th quarter. Hexagon Capital Partners LLC now owns 670 shares of the life sciences company's stock valued at $29,000 after buying an additional 370 shares during the last quarter. Gladius Capital Management LP bought a new stake in Integra LifeSciences during the 3rd quarter valued at $47,000. Valley National Advisers Inc. bought a new stake in Integra LifeSciences during the 1st quarter valued at $63,000. Finally, Covestor Ltd raised its holdings in Integra LifeSciences by 82.5% during the 3rd quarter. Covestor Ltd now owns 2,037 shares of the life sciences company's stock valued at $78,000 after buying an additional 921 shares during the last quarter. Hedge funds and other institutional investors own 84.78% of the company's stock.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.